🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Germany / NCT07674173
Recruiting Observational

Post-market European & Asian Registry to Evaluate the Minos™ Stent-Graft and Delivery System in Abdominal Aortic Aneurysm Treatment

NCT07674173 · tracked via the Priya Life Science Germany tracker
Phase
Observational
Started
2023-03-05
Last updated
2026-06-29

Condition(s) studied

Endovascular Repair of Infrarenal Abdominal Aortic Aneurysm Using Endovascular Stent Graft

Investigational drug(s) / intervention(s)

Implantation with Minos Stent graft

Implantation with Minos Stent graft: Treatment of subjects diagnosed with abdominal aortic aneurysm using the low-profile Minos Abdominal Aortic Stent-Graft and Delivery System. Follow up as per institutional standard of care.

Study summary

The Minos™ Abdominal Aortic Stent-Graft and Delivery System is a medical device designed to treat abdominal aortic aneurysms using a minimally invasive procedure. The device is placed inside the aorta through blood vessels, usually accessed through small incisions in the groin. The goal of this observational study is to collect short-, medium- to long-term safety and performance data of the Minos™ stent-graft in everyday medical practice (real-world settings). The aim is to study about 200 patients worldwide and at least 30 patients in European hospitals.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosis of infrarenal abdominal aortic aneurysm * Plan to treat with Minos Abdominal Aortic Stent-Graft and Delivery System * Voluntary participation and completion of Informed Consent Form, with willingness to participate in follow-up to 5 years post-procedure Exclusion Criteria: * Subjects in whom use of the Minos™ Abdominal Aortic Stent-Graft and Delivery System is contraindicated, as follows: * Severe stenosis or calcification near the aneurysm, leading to difficulty in achieving apposition of vessel wall and stent graft. * Difficult access due to severe stenosis or tortuosity in the iliac artery or femoral artery. * Subjects with ruptured aneurysm or acute aneurysm. * Subjects with an infectious aneurysm. * Those who are allergic to contrast agents or unable to tolerate contrast agents due to renal insufficiency. * Patients with severe coagulation disorder and/or high risk of postoperative hemorrhage. * Aneurysmal neck angulation greater than 60°. * Patients with blood supply to vital organs originating from the aneurysmal sac. * Patients with other comorbidities and whose life expectancy does not exceed one year. * Subjects with connective tissue diseases, such as Marfan syndrome. * Minors and pregnant women. * Subjects who are allergic to nitinol. * Subjects who are considered not suitable for treatment with stent graft.

Primary outcome measure(s)

Trial sites (16)

FacilityCityRegionStatus
The Second Hospital of Lanzhou University Lanzhou Gansu Recruiting
Meizhou People's Hospital Meizhou Guangdong Recruiting
The University of Hong Kong - Shenzhen Hospital Shenzhen Guangdong Recruiting
Hunan Provincial People's Hospital Changsha Hunan Recruiting
Xiangtan Central Hospital Xiangtan Hunan Recruiting
Yueyang Central Hospital Yueyang Hunan Recruiting
Zibo Central Hospital Zibo Shandong Recruiting
TEDA International Cardiovascular Hospital Binhai Tianjin Municipality Recruiting
Kunming Yan'an Hospital Kunming Yunnan Recruiting
Fuwai Hospital Beijing China Recruiting
Klinikverbund Allgäu Immenstadt im Allgäu Allgäu Recruiting
Universitätsklinikum Münster (UKM) Münster Germany Recruiting
"G. Gennimatas" Thessaloniki General Hospital Thessaloniki Greece Recruiting
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (ASST Spedali Civili di Brescia) Brescia Italy Not Yet Recruiting
Erasmus MC Rotterdam Netherlands Recruiting
Hospital Universitari de Girona Doctor Josep Trueta Girona Catalonia Not Yet Recruiting

More Shanghai MicroPort Endovascular MedTech(Group)Co., Ltd trials in Germany

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07674173 on ClinicalTrials.gov ↗ ← All trials in Germany